Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025HaematologicaOpen Access

Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties

View Full Paper
Ask AI
Bookmark
Share

Authors

QTQuentin Van ThilloCHCédric Hermans

Discussion

Loading...

Member takes

Overview

This review explores rebalancing agents targeting anticoagulants in hemophilia, highlighting metrics and uncertainties.

Key Points

  • Rebalancing agents show promise in improving the management of hemophilia and bleeding disorders, but they also introduce new risks.
  • Current treatments like Fitusiran and concizumab target different pathways, potentially enhancing thrombin generation.
  • Ongoing challenges include ensuring access in low-income regions and addressing thrombotic risks associated with these agents.
  • Further research is needed to understand the efficacy of these therapies compared to existing factor replacement treatments.

Cite This Study

Thillo et al. (2025) studied this question.

synapsesocial.com/papers/68c23e4fb210217d6479225dhttps://doi.org/10.3324/haematol.2025.288245
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Perspectives on Selected Hemophilia Research Presented at <scp>ISTH</scp> 2025: Nonfactor Replacement Therapies2025
  2. 2Redefining hemophilia management: treatment goals, nonfactor replacement therapies, and the role of fitusiran.2026 · 1 citations
  3. 3PO47 | Hemophilia A and antithrombin deficiency: a case of natural hemostatic rebalancing2025
  4. 4Evaluating reversal strategies for long-acting factor XI antibodies: RFVIIa®, FEIBA®, Kcentra®, novel FXI mutants, and an anti-idiotypic antibody2025
  5. 5Navigation of the Hemophilia Drug Choice-Paralysis: A Quick User Guide to New and Existing Therapies2025